Associated Papers
Germline mutation analysis and postoperative recurrence risk prediction in breast cancer patients from western China.
Deng Z et al.
Translational Oncology, 2025
40738016 (PubMed )
Supplement: mmc3.xlsx › Table_S2
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.
Li Y et al.
Hereditary Cancer in Clinical Practice, 2024
Patient tissue-derived FGFR4-variant and wild-type colorectal cancer organoid development and anticancer drug sensitivity testing.
Lin H et al.
Heliyon, 2024
38826758 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J et al.
Frontiers in Oncology, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
Cabral LKD et al.
Cancers, 2020
Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues.
Panvichian R et al.
Biomed Research International, 2015
Select a paper to view details